Jillian Michaels Warns of Gray Market Weight Loss Drug Risks

Fitness and wellness expert Jillian Michaels has warned Americans against a dangerous trend of buying unregulated “gray market” weight loss peptides online and self-dosing without medical supervision. In an interview with Fox News’ Alex Hogan, Fox News reported, Michaels cited severe health risks — including potential heart issues, vision loss, hormonal imbalances and suicidal ideation — and urged consumers not to take these drugs “into their own hands.”

Why This Matters

GLP-1 receptor agonists such as semaglutide and tirzepatide mimic natural hormones that regulate blood sugar and suppress appetite. FDA-approved versions like Ozempic, Wegovy, Mounjaro and Zepbound have transformed obesity treatment, but the “gray market” refers to unregulated, often foreign-sourced or compounded peptide products sold online — frequently labeled “for research purposes only” or “not for human consumption” — that bypass FDA review for safety, effectiveness and quality.

Compounding is legal under federal law, but only for patients whose medical needs cannot be met by an FDA-approved drug. Compounded drugs are not FDA-approved and do not undergo pre-market review.

Michaels’ Warning

Michaels said it is “not difficult to get” peptide drugs online, but consumers often do not know the true source of the products they are buying. She cautioned against dosing oneself “off of a Reddit forum.”

“These are very significant things that need to be further researched and discussed with your doctor before you decide, ‘Hey, this sounds like a miracle drug. And I’m buying it on the web, and I am dosing myself in the bathroom off of a Reddit forum,’” she told Fox News.

The wellness guru argued the surge in illegal sales is driven largely by people chasing quick “vanity pounds,” pointing to individuals in major cities who want to go from a “size eight to a size two” for summer vacation. She said the consequences are already visible in celebrities who “look gaunt, they look aged, they’re losing their hair.”

Michaels also warned that stopping unregulated compounds can trigger aggressive rebound hunger, because the drugs disrupt the body’s natural hormone production. “You’ll get a cycle of yo-yo dieting that you no longer know how to stop because you messed up your own biochemistry,” she said. “These things are not a joke, man. They are not something that you play around with for vanity purposes, for sure.”

She stressed, however, that FDA-approved GLP-1s can be appropriate under medical supervision for individuals with severe obesity or chronic health conditions.

Federal Crackdown

The federal government has escalated enforcement against illegal GLP-1 marketing. In March, the FDA announced it had issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products.

“Compounded drugs can be important for overcoming shortages or meeting unique patient needs, but compounders should not try to compound drugs in a way that circumvents FDA’s approval process,” FDA Commissioner Dr. Marty Makary said in a statement.

In June, the FDA issued a warning about unapproved GLP-1 drugs, noting that unapproved versions “do not undergo FDA’s review for safety, effectiveness and quality before they are marketed.” As of May 31, 2026, the agency had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, some requiring hospitalization. The FDA has also established an import alert to stop GLP-1 active ingredients with potential quality concerns from entering the U.S. supply chain, and has documented fraudulent products whose labels list pharmacies that do not exist.

Analysis

The warning arrives at a moment of intense regulatory and cultural pressure. Michaels’ broader critique of the “healthmaxxing” trend — a viral social media phenomenon in which 70% of Gen Z feels pressure to keep up with extreme health standards — connects consumer demand to influencer culture. In a related Fox News video, Michaels dissects the trend and advocates for doctor consultations over unregulated online advice.

Meanwhile, an FDA advisory committee recently voted to expand access to several popular peptides, adding another layer to the policy debate over how these drugs should be regulated. The combination of widespread gray-market availability, social media pressure and celebrity transformations may push more consumers toward self-dosing, even as the FDA documents serious adverse events.

What’s Next

Regulators and public health advocates will be watching whether increased enforcement and high-profile warnings shift consumer behavior. For now, Michaels’ advice is straightforward: consult a doctor, avoid unregulated products and treat these powerful drugs with caution. The FDA urges consumers to obtain prescriptions from licensed doctors, fill them at state-licensed pharmacies and report any adverse events through its MedWatch program.